Infectious agents have been proposed as one of the risk factors for schizophrenia. However, the data on the association of infectious agents with in vivo brain changes are scant. We evaluated the association of serological evidence of exposure to herpes simplex virus 1 (HSV1) with in vivo brain structural variations among first-episode antipsychotic-naive schizophrenia/ schizoaffective disorder patients and control subjects. We assayed HSV1 immunoglobulin G (IgG) antibody in serum samples from 30 patients and 44 healthy subjects and obtained structural magnetic resonance imaging scans from the same individuals. There were proportionately more patients with elevated HSV1 antibody ratios than healthy comparison subjects (v 2 = 3.98, 1 df, P = 0.046) and patients had significantly higher HSV1 IgG antibody ratios compared with healthy subjects. Using optimized voxel-based morphometry, we examined diagnosis by HSV1 serological status interaction followed by within-and betweengroup comparison across the serological status. We observed a diagnosis by HSV1 serological status interaction and a significant main effect of HSV1 serological status in the prefrontal gray matter. Patients exposed to HSV1 had decreased gray matter in Brodmann area 9 (dorsolateral prefrontal cortex) and 32 (anterior cingulate cortex) compared with patients without serological evidence of exposure to HSV1. HSV1-associated differences in brain structure were not detected among healthy subjects. These findings suggest that HSV1 exposure in schizophrenia is associated with specific regional gray matter differences that may not be attributable to medications, illness chronicity or comorbid substance use. This study provides suggestive evidence for a link between HSV1 exposure and some of the cerebral morphological changes often reported in schizophrenia.
Introduction
Plausible environmental as well as genetic etiological factors for schizophrenia have been proposed, but the pathogenic mechanisms are still unclear. Exposure to infectious agents has been proposed as one of the putative environmental factors. The support for the role of infectious risk factors comes from direct and indirect lines of investigation. A review of more than 250 studies concluded that there was nearly 5-8% excess winter or spring births for individuals who later develop schizophrenia. 1 Several factors, including infectious agents may explain this excess. Other studies have noted higher numbers of these births during the periods of increased activity of infectious agents. 2 Herpes virus DNA has been identified in the brains of schizophrenia patients 3, 4 and elevated antibody levels to herpes simplex virus (HSV) in schizophrenia patients in some, [5] [6] [7] [8] but not all studies. [9] [10] [11] Among the infectious agents reported so far, herpes viruses are particularly interesting. They belong to herpesviridae family and are characterized by an electron opaque core of double stranded DNA surrounded by a protein capsid, an amorphous tegument surrounding the capsid with an outer spiky envelope. 12 Following infection, the viral DNA integrates into the host cell DNA and establishes latency in the nervous system with periodic lytic cycles 13 that can remain lifelong. Among the herpes viruses, HSV1, HSV2, cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV) and human herpes virus 6 (HHV6) have neurotrophic potential. 12 The central nervous system infection of CMV, 14 EBV 15 and VZV 16 in immunocompetent persons is rare. HSV2
infection of brain usually occurs in neonates. 17 Both HSV1 18 and HHV6 19 can cause central nervous system infection in immunocompetent persons. Herpes virus infection of the central nervous system can lead to acute encephalitis but can also cause self-limited infection. 20 In human beings, latent HSV1 infection is maintained primarily in the trigeminal ganglia, although evidence for latent infection in cornea, brain and other non-brain tissues is mounting. 21 Reactivation of latent infection may be brought about by physical or emotional stress, 22 menstruation 23 and hormonal imbalance. 24 The impact of reactivation on brain function has not been investigated extensively.
HSV1 could contribute to the pathogenesis of schizophrenia through several putative mechanisms. Animal studies have revealed impaired sensori-motor gating in rats infected with HSV1 virus during the early post-natal period. 25 Abnormalities in sensorimotor gating has been consistently reported in schizophrenia. 26 Besides, maternal immune response to infections can also induce abnormal behavioral responses in the offspring. 27 Therefore, infection early in life may affect neurodevelopmental processes and thus lay the foundations for psychopathology later in life. During reactivation lytic cycles, HSV1 viruses propagate to frontal, temporal and other brain regions. Repeated reactivation could lead to cell death 21 in these brain regions that have been implicated in schizophrenia. In addition, increased brain dopamine, norepinephrine and serotonin have been observed in experimental HSV1 infection in animals. 28, 29 Abnormalities in these neurotransmitters have been consistently reported to be associated with psychotic symptoms 30 and cognitive deficits such as working memory. 31 Working memory deficits have been reported among schizophrenia patients exposed to HSV1. 32 Increased symptom severity has also been associated with viral infections. 7 Thus, putative links between HSV1 and schizophrenia have been provided by epidemiologic, animal and postmortem studies. Examination of in vivo brain changes could provide important additional evidence and clarify links between these infections and pathogenesis.
Magnetic resonance imaging (MRI) is the most sensitive non-invasive technique for the diagnosis of acute HSV encephalitis in its early stages. 33 Distinct brain regions such as the frontal and temporal lobes, and the insular cortex have been reported to show higher signal intensity in T2-weighted images in acute HSV1 encephalitis 34 possibly reflecting underlying tissue destruction owing to the infection. In a case report, progression of MRI abnormalities was observed even after the patient improved clinically and the polymerase chain reaction test of cerebrospinal fluid (CSF) was negative for HSV1 DNA. 35 There are no reports of such MRI pathology among schizophrenia patients exposed to HSV1. One study that examined brain structure using MRI observed brain changes related to high HSV1 serum antibody levels. 36 This study was conducted on medicated schizophrenia patients. Moreover, MRI scans utilized 8-mm thick slices and the analysis was limited by the method used to measure the frontal area and cortical atrophy. We examined in vivo gray matter changes associated with HSV1 infection among first-episode, antipsychotic-naive schizophrenia patients and healthy subjects using high resolution structural MRI. We hypothesized that schizophrenia patients and healthy subjects exposed to HSV1 would show temporal and frontal gray matter changes compared to those without the exposure to infection. We further hypothesized that schizophrenia patients exposed to HSV1 infection would show greater reduction in gray matter in these brain regions compared to those not exposed to the infection. 37 diagnoses were derived by reviewing Structured Clinical Interview for DSM-IV 38 data and data from medical records in a consensus diagnostic conference of senior clinicians (MSK, GLH, CSC and NRS). All diagnoses were confirmed by following these subjects for a minimum of 6 months. We also obtained demographic information including the socio-economic status (SES) using the Hollingshead scale. 39 Healthy subjects were recruited through local advertisements from the same geographic region as the patients. None of the subjects had an IQ less than 80, substance dependence in the last 6 months or abuse in the month before participation. Subjects with medical or neurological disorders including head injury, encephalitis and epilepsy were not recruited. After fully explaining the experimental procedures, informed consents were obtained from all subjects. The Institutional Review Board of the University of Pittsburgh approved the study.
Subjects and methods

Subjects
Imaging methods MRI scans were obtained on 74 subjects using a GE 1.5T whole body scanner (GE Medial Systems, Milwaukee, WI, USA). The detailed scanning protocol has been described in our earlier publication. 40 Briefly, the scans were three-dimension spoiled gradient recalled, acquired in a steady-state pulse sequence (124 coronal slices, 1.5 mm thickness, echo time = 5 ms, repetition time = 25 ms, acquisition matrix = 256 Â 192, field of view = 24 cm, flip angle 401). Images with motion artifacts were not included in the study.
Images were analyzed using the Statistical Parametric Mapping (SPM2) software (http://www.fil. ion.ucl.ac.uk/spm/software/spm2/). The voxel-based morphometry (VBM) analysis was implemented on a Linux workstation using the SPM2 package on a Matlab 7 platform.
41 SPM2 offers several advantages over the previous version such as updated segmentation procedure and correction for misclassified nonbrain tissue. We performed voxel-by-voxel analysis using a previously published method. 42 We initially generated a study-specific template by including the scans of all subjects obtained from the same scanner using the identical protocol described above. The MR images were normalized to the standard T1 template and segmented into gray matter, white matter and CSF depending on the intensity and the spatial probability of that voxel belonging to any of these tissue categories. Finally, the images were smoothed by convolving with a Gaussian smoothing kernel (12 Â 12 Â 12 FWHM) in order to reduce noise. This study-specific gray matter template was used to normalize the extracted gray matter maps of individual MRI scans. The normalization procedure was reapplied to the original images to obtain optimized segmentation of normalized images. In order to correct for volume changes, segmented images were modulated by the Jacobian determinants from spatial normalization. Modulated images were then smoothed with a 12 Â 12 Â 12 FWHM Gaussian kernel. These modulated images were used to extract gray matter volumes from regions of interest. We extracted the total brain volume (TBV) from these images and used it as a covariate when performing between-group comparisons. We preferred to use VBM approach because this method would offer a whole brain analysis as opposed to region-of-interest approach. A previous study using VBM to compare patients who have recovered from HSV1-encephalitis with matched controls has demonstrated the usefulness of this method. 43 
Immunological assays
The immunoglobulin (Ig)G antibodies to HSV1 were tested with solid-phase enzyme immunoassay directed at the HSV1-specific gG1 glycoprotein. 32, 44 Assays using different microtiter plates were standardized by using reference samples run on each assay plate. Antibody titers were quantified as signal/cutoff (S/C) ratios, which were calculated for each sample by dividing the optical density measurements generated in the assay by the optical density of a standard cutoff serum. An S/C ratio of X1.0 was considered to be indicative of serological evidence of HSV1 infection. 32 In this study, the antibody ratios were bimodally distributed with the trough at approximately 1.3. Subjects with antibody ratios greater than 1.3 were considered individuals with serological evidence of HSV1 exposure (HSV1 seropositive) and those with less than 1.3 were considered individuals without serological evidence of HSV1 exposure (HSV1 seronegative).
Statistical plan
First, we examined differences in demographic and clinical characteristics among patients and control individuals (Table 1) . Next, we examined differences in IgG antibody ratios as well as group differences in seropositivity for HSV1. Subsequently, we examined the gray matter maps for differences between cases and controls, followed by within-and betweengroups differences based on seropositivity using age, sex, SES and race as covariates. After extracting the volumes, we used multivariate analysis of variance (MANOVA) to test the overall model significance including all brain regions that were different in the VBM and then the between-subjects effects. While examining group differences between patients and healthy comparison subjects, we used TBV as a covariate.
Results
Serology
There were significantly more HSV1-seropositive patients among schizophrenia patients than among healthy control subjects (w 2 = 3.98, 1 df; P = 0.046). Among schizophrenia patients, 50% were HSV1 seropositive, whereas 18.9% of the healthy subjects were HSV1 seropositive. HSV1 IgG antibody ratios were significantly increased among patients compared to healthy control subjects after covarying for age, SES and race (mean ratios, patients 1.6271.38, controls, 0.8971.12, ANCOVA, F(4, 74) = 6.66, P = 0.012).
Brain morphometry
Diagnosis by HSV1 status interaction. A significant interaction between the diagnosis and HSV1 exposure was observed at the bilateral middle frontal gyrus (Brodmann area (BA) 9) (F(1, 69) = 3.29, P < 0.001) and the right posterior fusiform gyrus (F(1, 69) = 4.21, uncorrected P < 0.0001). After extracting volumes from these regions, we performed a MANOVA including the volumes of the regions that showed a significant HSV1 status and diagnosis interaction. We observed statistically significant interaction for the volumes (Wilk's l = 0.856, F = 3.80, P = 0.014) and a significant main effect of serological evidence of HSV1 exposure (Wilk's l = 0.867, F = 3.48, P = 0.021) (Figure 1 ). However, we did not observe main effect of diagnosis in this sample (Wilk's l = 0.971, F = 0.67, P = 0.57, NS). Tests of between-subjects effects showed that the interaction term was significant at BA 9 (left, F(1, 74) = 11.18, P = 0.001; right F(1, 74) = 4.30, P = 0.042) with a trend at the right posterior fusiform gyrus (F(3, 74) = 3.07, P = 0.084). The main effect of HSV1 serological status showed trends toward significance at left BA 9 (F(1, 74) = 3.10, P = 0.083), right BA 9 (F(1, 74) = 2.80, P = 0.099) and was significant at the fusiform gyrus (F(1, 74) = 9.75, P = 0.003). We did not observe the main effect of diagnosis on any of these brain regions in this sample.
Within-group comparisons based on HSV1 serological status Among schizophrenia subjects, HSV1-seropositive patients had reduced gray matter in the prefrontal regions compared to HSV1-seronegative patients. We observed bilateral reduction in gray matter intensity in BAs 9 (coordinates: 52, 7, 36; À49, 12, 24) and 32 (anterior cingulate cortex; coordinates: 12, 16, 62; À11, 29, 42) (uncorrected P < 0.001 for both regions; Figure 2 ). Next, we performed withingroup comparison using MANOVA by including the volumes extracted from these brain regions. HSV1 serological status was significantly associated with the volumes of these regions in the multivariate model (Wilk's l = 0.67, F = 3.08, P = 0.034). Tests of between-subjects effects showed that these regions were significantly reduced in volume among HSV1-seropositive patients compared to HSV1-seronegative patients ( Table 2 ). The right BA 9 was reduced by 6.24%, whereas the left was reduced by 4.95%. Right anterior cingulate gyrus (BA 32) was reduced by 5.84% and the left was reduced by 6.31%. We did not observe such differences among the healthy subjects except for a reduction in area 6 (motor cortex).
Between-groups comparison based on HSV1 serological status
We examined gray matter differences between HSV1-seropositive schizophrenia patients and HSV1-seropositive healthy comparison subjects. HSV1-seropositive patients had significant reductions in gray matter intensity in the prefrontal regions compared to HSV1-seropositive healthy subjects (area 9, coordi- Figure 3) . We, next, conducted MANCOVA by including the extracted volumes of these regions, using TBV as a covariate. HSV1-seropositive patients showed significant reduction in gray matter compared to HSV1-seropositive healthy subjects (Wilk's l = 0.42, F = 16.00, P = 0.00004). Both BAs were reduced in HSV1-seropositive patients compared to HSV1-seropositive healthy subjects (Table 2) . Estimated mean volume of BA 9 in HSV1-seropositive patients was reduced by 6.79% compared to HSV1-seropositive healthy subjects.
BA 8 showed a greater reduction (10.28%) in HSV1-seropositive patients compared to HSV1-seropositive healthy subjects. HSV1-seronegative patients showed reductions in gray matter intensity in the left anterior cerebellar lobe (À12 À54 À9) and right inferior temporal gyrus (60 À24 À26) (uncorrected P < 0.001). However, on performing MANCOVA using TBV as a covariate, the volumetric reductions were not statistically significant (Wilk's l = 0.95, F = 1.22, P = 0.31, NS; anterior cerebellum, F(1, 47) = 2.47, P = 0.12, NS; inferior temporal gyrus, F(1, 47) = 0.62, P = 0.43, NS). HSV1 and brain morphology in first-episode schizophrenia KMR Prasad et al
Discussion
We report decreased prefrontal gray matter volume among HSV1-seropositive first-episode antipsychoticnaive schizophrenia/schizoaffective disorder patients compared to HSV1-seronegative patients. A similar reduction in prefrontal gray matter was also observed when the HSV1-seropositive patients were compared with HSV1-seropositive healthy control subjects. These changes may not be due to confounds such as psychotropic medication exposure and/or illness chronicity. Furthermore, these differences were observed after covarying for the effects of age, gender, race and SES. Interestingly, we did not observe gray matter differences in the hypothesized regions in HSV1-seropositive healthy control subjects compared to HSV1-seronegative healthy subjects. However, we observed reduction in the motor cortex gray matter in HSV1-seropositive healthy subjects compared to HSV1-seronegative healthy subjects. The significance of this observation is unclear. Such differences have not been reported in the literature. Further, we observed an interaction between diagnosis and HSV1 serological status. The brain regions where morphometric changes have been observed in this study represent some of the regions where HSV1 viruses are known to propagate after reactivation. Our observation supports a recent report on the association of working memory deficits in schizophrenia patients exposed to HSV1.
32
The HSV1-associated brain structural changes in first-episode antipsychotic-naive patients but not in healthy subjects is unexpected and intriguing. We expected to observe such differences in both patients and healthy subjects. It suggests that HSV1 exposure interacts with illness-related variables, leading to the observed brain structural alterations. The illness-related variables are not precisely known, but they could include host response to HSV1 exposure as well as genetic factors. The host response to HSV1 infection may partly determine the pathogenesis of HSV1-associated brain alterations. It is unclear whether subjects vulnerable to develop schizophrenia mount a different type of host response to HSV1 compared to those who do not. Although it is tempting to postulate based on our data on HSV1 antibody levels that schizophrenia patients may show a more 'vigorous' immune response, such differences could be influenced by factors such as recency of infection and the infectious phase at which the blood was collected. Animal studies have shown that circulating glucocorticoids play a permissive role in inducing the host immune response and behavioral changes such as increased locomotion and aggression. 24 Interestingly, several studies have reported elevated cortisol levels, increased production of interleukin-2 (IL-2) and IL-6 45, 46 and increased volume of the pituitary gland 47, 48 in schizophrenia patients compared to healthy controls. IL6 has been shown to stimulate the hypothalamicpituitary axis 46 thus possibly setting up a vicious circle that may confer vulnerability to brain structural alterations in schizophrenia patients but not in healthy subjects.
Although the prefrontal region has been implicated in the pathogenesis of schizophrenia, [49] [50] [51] [52] prefrontal morphological changes have remained inconsistent. 49 Although this may partly be due to inadequate power of some of the samples, the inconsistencies may also reflect biological heterogeneity. In this study, we did not observe a main effect of diagnosis but did observe a main effect of HSV1 status and an interaction effect of HSV1 status and diagnosis. Our previous studies have revealed that variations in the genes encoding 54 were associated with alterations in prefrontal cortex volume in first-episode, antipsychotic-naive schizophrenia/schizoaffective disorder patients but not in controls. It has been proposed that some genetic factors may confer vulnerability to cerebral morphological changes or induce subtle changes (e.g., RGS4 that affects neuroplasticity 55 or neuronal migration 56 ). It is plausible that interactions between such genetic variants and environmental factors such as HSV1 infection or stress associated with such infection modify the structural changes. One recent animal study examined the association of influenza A virus infection with the expression of synaptic regulatory proteins and cognitive differences in mice. 57 The investigators found increased expression of RGS4 and calcium/ calmodulin-dependent protein kinase IIa (CaMK2A) transcripts in specific regions of the brain. However, it is not known whether HSV1 infection leads to such alterations in gene expression. Interestingly, HSV1 has been shown to cause apoptosis of neural cells during acute infection but not in late sequelae. 58 Illness-related factors may modulate apoptotic process induced by HSV1. Such interactions need to be tested in sufficiently powered samples comprising human subjects.
The increased prevalence of HSV1 seropositivity and elevated antibody ratios among first-episode patients suggest that HSV1 may be a risk factor for schizophrenia, though the difference could also be explained by ascertainment bias. We did not observe differences in antibody levels for other Herpes viruses such as HSV2 and CMV between patients and controls in our dataset suggesting that increased antibody ratios in HSV1 may not be nonspecific. Other studies on schizophrenia patients that do not report increased prevalence or elevated antibody levels, 59, 60 do not include first-episode medication naive patients. Inclusion of chronically ill individuals could arguably be less sensitive to changes evident at the onset of illness. Leweke et al. 60 included early course antipsychotic-naive patients (n = 36) who were considerably older than the patients in our study. The duration of untreated illness in this study is also unclear. It is not known what, if any impact these variables have on the putative association. Studies with larger samples of first-episode schizophrenia may offer definitive answers to this question.
It is intriguing to examine whether schizophrenia/ schizoaffective disorder patients with gray matter abnormalities suffer from acute or latent infection with reactivation. One approach could be to measure IgM antibody levels along with IgG that could suggest the temporal association of infection with the brain structural alterations. However, IgM antibodies may be sensitive to newly acquired infection and may not be sensitive to reactivated latent infection. A postmortem study noted that immune cell infiltration in the trigeminal ganglia of patients who had HSV1 infection correlated significantly with reactivation compared to those whose trigeminal ganglia was not infiltrated. This correlation was specifically found for infiltration of T cells with CD3 and CD8 markers, and CD68 macrophages and expression of latency-associated transcript (LAT) suggesting such markers could indicate those vulnerable to develop latent infection. 61 To our knowledge, there are no reliable and specific markers to examine whether a person has acute infection as opposed to latent infection although knockout studies in mice have shown that CD4 and CD8 cells play a role in the pathogenesis of recurrent infection. 62 In our study, it was hard to determine whether the subjects had acute or reactivated latent infection.
Possible cellular and molecular events associated with gray matter changes in HSV1-seropositive subjects is equally intriguing and merits discussion. To our knowledge, the data that specifically links gray matter alterations with molecular and cellular events in schizophrenia subjects with serological evidence of HSV1 exposure do not exist. However, neuronal apoptosis following acute HSV1 infection but not in chronic states has been demonstrated. 58 A complex interaction of HSV1 virogenes and their products with the neuronal apoptotic process has also been observed. 63 HSV1 infection during the early brain development periods have been shown to cause chromosome damage that may show later cerebral and behavioral abnormalities. 64 Interestingly, chromosome breaks, pulverization and uncoiling of centromeres of chromosomes 1, 9 and 16, 65 with chromosome regions 1p32, 1q32 and 3p21 being the most susceptible 66 have been demonstrated. These observations were made on peripheral leukocytes, and human embryonic kidney and lung cells. These findings need to be replicated in human neuronal cells. Such observations lead one to speculate that these mechanisms may be operating in schizophrenia subjects who have shown gray matter changes. Besides, except for a case report mentioned earlier, we are not aware of systematic studies on the progressive nature of cerebral pathology in patients who have recovered from HSV1 encephalitis. Further, we are also unaware of such data in schizophrenia patients.
In conclusion, to our knowledge this is the first systematically conducted study to observe an association of brain morphological changes to a viral agent in schizophrenia. Our observations may be clinically significant and raise the intriguing possibility of antiviral therapy for schizophrenia. Interestingly, a recent report found a significant improvement in psychotic symptoms in schizophrenia patients seropositive for CMV treated with valacyclovir. 67 Future studies are needed to replicate our findings using larger samples of first-episode patients. The confirmation of this association might lead to new methods for the diagnosis and management of individuals with first-episode schizophrenia.
